Biotech | November 12, 2025
Samsung Epis launches new biotech subsidiary Epis NexLab
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The antibody was designed and developed at Abzena’s Cambridge, UK,
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Subscribe To Our Newsletter & Stay Updated
